Autolus Therapeutics plc - American Depositary Share (AUTL): Price and Financial Metrics

Autolus Therapeutics plc - American Depositary Share (AUTL)

Today's Latest Price: $16.00 USD

0.03 (-0.19%)

Updated Jul 1 6:55pm

Add AUTL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

AUTL Stock Summary

  • AUTL's went public 2.02 years ago, making it older than only 4.97% of listed US stocks we're tracking.
  • AUTL's price/sales ratio is 563.52; that's higher than the P/S ratio of 99.15% of US stocks.
  • As for revenue growth, note that AUTL's revenue has grown -55.72% over the past 12 months; that beats the revenue growth of just 2.93% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Autolus Therapeutics plc, a group of peers worth examining would be ARNA, ASND, CRNX, QURE, and FATE.
  • Visit AUTL's SEC page to see the company's official filings. To visit the company's web site, go to
AUTL Daily Price Range
AUTL 52-Week Price Range

AUTL Stock Price Chart Technical Analysis Charts

AUTL Price/Volume Stats

Current price $16.00 52-week high $19.34
Prev. close $16.03 52-week low $3.00
Day low $15.88 Volume 223,000
Day high $16.25 Avg. volume 183,452
50-day MA $12.19 Dividend yield N/A
200-day MA $11.26 Market Cap 642.34M

Autolus Therapeutics plc - American Depositary Share (AUTL) Company Bio

Autolus Therapeutics is developing a pipeline of advanced programmable T cell treatment candidates for blood and solid tumor cancers. Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I), or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma. The company is based in London, England.

AUTL Latest News Stream

Event/TimeNews Detail
Loading, please wait...

AUTL Latest Social Stream

Loading social stream, please wait...

View Full AUTL Social Stream

Latest AUTL News From Around the Web

Below are the latest news stories about Autolus Therapeutics plc that investors may wish to consider to help them evaluate AUTL as an investment opportunity.

Moving Average Crossover Alert: Autolus Therapeutics

Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Yahoo | June 24, 2020

Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting

Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 - 24, 2020. “Behind our lead programs AUTO1 in ALL and AUTO3 in DLBCL, we have a number of exciting preclinical product candidates progressing towards the clinic,” said Dr Christian Itin, chairman and chief executive officer of Autolus.

Yahoo | June 22, 2020

Is Autolus Therapeutics PLC Sponsored (AUTL) Stock Outpacing Its Medical Peers This Year?

Is (AUTL) Outperforming Other Medical Stocks This Year?

Yahoo | June 19, 2020

Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress

Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program, the company’s CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study of relapsed / refractory adult B-Acute Lymphocytic Leukemia (ALL), at the European Hematology Association EHA25 Virtual Congress beginning June 11. As of the data cut-off date of May 13, 2020, 19 patients had received AUTO1. AUTO1 was well tolerated, with no patients experiencing ≥ Grade 3 CRS.

Yahoo | June 12, 2020

Autolus Therapeutics (AUTl) Investor Presentation - Slideshow

The following slide deck was published by Autolus Therapeutics plc in conjunction with this event....

SA Transcripts | June 9, 2020

Read More 'AUTL' Stories Here

AUTL Price Returns

1-mo 25.10%
3-mo 197.40%
6-mo 23.93%
1-year -2.02%
3-year N/A
5-year N/A
YTD 21.21%
2019 -59.81%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0007 seconds.